Category Archives: Gene Therapy Clinics

Cancer Biological Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to 2025 -…

A new business intelligence Report Global Cancer Biological Therapy Marketis made covering in-depth analysis by manufacturers and key business segments. The report probes into the current trends, market drivers, growth opportunities, and restraints that are likely to impact the dynamics of the Cancer Biological Therapy Market over the forecast period 2020 2025. Cancer Biological Therapy Market Report presents a professional and deep analysis on the present state of Cancer Biological Therapy Market that Includes major types, major applications, Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export and etc. Industry chain, manufacturing process, cost structure, marketing channel are also analysed in this report.

Introduction:, Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use., , , Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the bodys immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies. , The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period., , , EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon., , , On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015. , On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.

Are You A Start-Up On The Way To Make It Vast? Grab an Free Exclusive Sample Copy of Cancer Biological Therapy Report Here @ https://www.esherpamarketreports.com/request-sample/es-193383/

Objective of Studies:

Cancer Biological Therapy Market Statistics by Types:

Cancer Biological Therapy Market Outlook by Applications:

Want To Institute Strategies For Upcoming Years? Our Reports Can Assist You To Plot Superior. Inquire Here @ https://www.esherpamarketreports.com/pre-order-enquiry/es-193383/

Key Question Answered in Report.

Reasons to Buy the Report:

Market Size Forecasts:The authors of the report have provided accurate estimation of the global Cancer Biological Therapy market size based on value and volumeMarket Trend Analysis:This section of the report throws light on the approaching trends and developments in the global Cancer Biological Therapy marketFuture Prospects:The report here offers crucial information on the rewarding opportunities in the global Cancer Biological Therapy marketRegional Analysis:Inclusive analysis of the potential regions and their countries in the global Cancer Biological Therapy market is provided in this part of the reportSegmental Analysis:Here, key segments comprising product type, application, and end user and their contribution to the overall market size are discussed in detailCompetitive Landscape:Market participants will get an overview of the business strategies considered by their competitors to stay ahead of the curve. This analysis will help the players to make informed business decisions in future.

Purchase this Report with Full Access & Complete TOC @ https://www.esherpamarketreports.com/purchase/es-193383/

Table of Contents:1 INTRODUCTION1.1 Definition1.2 Scope of Study1.2.1 RESEARCH OBJECTIVE1.2.2 ASSUMPTIONS & LIMITATIONS1.2.2.1 ASSUMPTIONS1.2.2.2 LIMITATIONS1.3 MARKET STRUCTURE:2 RESEARCH METHODOLOGY2.1 RESEARCH PROCESS:2.2 Primary Research2.3 SECONDARY RESEARCH:3 MARKET DYNAMICS3.1 DRIVERS3.1.1 GROWING Demand for newly developed Cancer Biological Therapy3.1.2 Growing trend of Outsourcing3.1.3 Growing Cancer Biological Therapy Industry in developing nations3.2 RESTRAINTS3.3 OPPORTUNITIES3.4 MACROECONOMIC INDICATORS4 MARKET FACTOR ANALYSIS4.1 Porters Five forces Model4.2 Bargaining power of suppliers4.3 BARGAINING POWER OF BUYERS4.4 THREAT OF NEW ENTRANTS4.5 Threat of Substitutes4.6 Intensity of Rivalry5 global Cancer Biological Therapy market, by Type6 global Cancer Biological Therapy market, By Application7 global Cancer Biological Therapy market, By Manufacturing Methods7.1 In-House Manufacturing7.2 Contract Manufacturing7.2.1 introduction8 Global Cancer Biological Therapy market, by region8.1 North America8.1.1 Introduction8.2 Europe8.2.1 Introduction8.3 Asia-Pacific8.3.1 introduction8.4 Middle East & Africa8.4.1 Introduction9 Competitive landscape9.1 Major Strategies adopted by market players9.1.1 STRATEGIC PARTNERSHIP9.1.2 Merger & Acquisition10 company profile

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

Click Here For Other Reports

Swimming Goggles Market By Application Analysis, Regional Outlook, Competitive Strategies And Forecast By 2025

world remotely operated vehicle rov Market 2020: Product Overview and Scope, Growth Rate and Price Analysis by Type, Forecast to 2025

Cooling Water Treatment Chemicals Market Analysis and In-Depth Research On Market Dynamics, Trends, Emerging Growth Factors and Forecasts to 2025

Read more from the original source:
Cancer Biological Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to 2025 -...

Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) – Expedition 99

Global Age Related Macular Degeneration (AMD) Marketwas valued US$ XX Bn in 2018 and is expected to reach XX Bn by 2026, at a CAGR of XX % during a forecast period.

Age-related macular degeneration is the prominent cause of severe, irreversible vision loss in people over age 60. It occurs when the small central portion of the retina deteriorates.

Growing population across the globe and the demography reflecting the predominance of the older population, the global affliction of AMD continues to increase at an unprecedented rate. The development of gene therapy for AMD, the growth in the geriatric population, and awareness concerning the AMD are some major factors behind the growth of the global age-related macular degeneration (AMD) market. Additionally, High prevalence of AMD is one of the key drivers in the global age-related macular degeneration (AMD) market. Factors like aging, smoking, high cholesterol, and high blood pressure are causing the prevalence of AMD.

On the other hand, high cost of the treatment, off label usage and strict regulatory policies are some of the factors, which are expected to limit the growth in the global age-related macular degeneration (AMD) market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36109

The risk of the occurring the AMD is directly proportional to the age. With the number of people aged above 60 years, the prevalence of AMD is also growing. In 2017, there were, about XX Mn people in the age group 60 years over across the globe, and the number is projected to grow XX Bn during the forecast period. So, the geriatric population is growing faster than younger age groups.

Wet Age-related Macular Degeneration (WAMD) treatment is expected to contribute significant share in the Global Age-Related Macular Degeneration (AMD), market. For wet AMD treatment, the anti-vascular endothelial growth factor is commonly used, which helps to pause or delay the progression of visual loss. By delaying the action of VEGF chemical, it aids to prevent the condition from progressing and partially reverse it. Anti-VEGF medicines include Eylea, Lucentis and Avastin.

Region-wise, The Asia Pacific region is projected to be leading region in the Global age-related macular degeneration (AMD) market. The market in the Asia Pacific region is set to experience favourable growth, which is driven by factors like the elderly population & rising health care expenditure. An increase in the obese population and economic development are also expected to boost the growth in the age-related macular degeneration (AMD) market.

A rise in the number of pipeline drugs for age-related macular degeneration is facilitating the industry key players to sustain in the global age-related macular degeneration market. Additionally, fast track drug designations and regulator government policies like tax benefits are some of the prominent factors aiding the new key players to enter in the age-related macular degeneration market. For instance, Fovista, which is a product of Ophthotech received fast track designation by U.S. FDA and launched in 2018.

The objective of the report is to present comprehensive analysis of global age related macular degeneration (AMD) market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or

negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.The report also helps in understanding global age related macular degeneration (AMD) market dynamics, structure by analysing the market segments, and project the global age related macular degeneration (AMD) market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the global age related macular degeneration (AMD) market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/36109

The Scope of the Report for Global Age Related Macular Degeneration (AMD) Market

Global Age Related Macular Degeneration (AMD) Market, By Type

Dry Age-related Macular Degeneration (DAMD) Wet Age-related Macular Degeneration (WAMD)

Global Age Related Macular Degeneration (AMD) Market, By Drug

Lucentis Eylea Avastin Others

Global Age Related Macular Degeneration (AMD) Market, By Stages

Intermediate Stage Age Related Macular Degeneration Early-Stage Age Related Macular Degeneration Late Stage Age Related Macular Degeneration

Global Age Related Macular Degeneration (AMD) Market, By Route ofAdministration

Intravenous Intravitreal

Global Age Related Macular Degeneration (AMD) Market, By Age Group

Above 75 Year Above 60 Year Above 40 Year

Global Age Related Macular Degeneration (AMD) Market, By End User

Hospitals & Clinics Dignostic Centers Academic Research Institutes

Global Age Related Macular Degeneration (AMD) Market, By Region

North America Europe Asia Pacific Middle East & Africa South America

Key players operating in Global Age Related Macular Degeneration (AMD) Market

Kubota Pharmaceutical Holdings Co. Ltd. Alimera Sciences Inc. Adverum Biotechnologies Inc. Gilead Sciences Inc. Apellis Pharmeceuticals Inc. F. Hoffmann-La Roche Ltd. Allergan plc. Bausch Health Companies Inc. Regeneron Pharmaceuticals Inc. Neurotech Pharmaceuticals Inc. Ophthotech Corporation Novartis AG Pfizer Inc. GlaxoSmithKline plc. Bayer AG

Browse Full Report with Facts and Figures of Age Related Macular Degeneration Market Report at:https://www.maximizemarketresearch.com/market-report/global-age-related-macular-degeneration-amd-market/36109/

MAJOR TOC OF THE REPORT

Chapter One: Age Related Macular Degeneration Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Age Related Macular Degeneration Market Competition, by Players

Chapter Four: Global Age Related Macular Degeneration Market Size by Regions

Chapter Five: North America Age Related Macular Degeneration Revenue by Countries

Chapter Six: Europe Age Related Macular Degeneration Revenue by Countries

Chapter Seven: Asia-Pacific Age Related Macular Degeneration Revenue by Countries

Chapter Eight: South America Age Related Macular Degeneration Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Age Related Macular Degeneration by Countries

Chapter Ten: Global Age Related Macular Degeneration Market Segment by Type

Chapter Eleven: Global Age Related Macular Degeneration Market Segment by Application

Chapter Twelve: Global Age Related Macular Degeneration Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Here is the original post:
Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) - Expedition 99

UAB: 50 years of Improving Birmingham, Alabama and the World – Birmingham Times

UAB Magazine

Written by Charles Buchanan, Brett Bralley and Jay Taylor with editorial contributions from Matt Windsor and UAB Public Relations. Images from UAB Archives, Rachel Hendrix, Andrea Mabry, Sarah Parcak, Steve Wood and Getty Images. Web design by Tyler Bryant. Reprinted by permission of UAB Magazine.

UABs birth was like a ray of sunlight punching through the smog.

In 1969 the newly independent university, uniting a pioneering academic medical center and a growing extension center, brought the promise of a brighter future to a city eager for change.

Birmingham is better because of UAB. So are Alabama, America, and the world. In the following pages, discover some of the many ways that UAB has fulfilled its promiseby saving lives, solving problems, expanding knowledge, and opening doorsover 50 years.

1

Best of the best

UABs accolades shine a global spotlight on Birmingham and Alabama:

2

A way to retrain the brain

Most scientists once believed that neuroplasticitythe brains ability to grow or repair itselfended in childhood. But research by UAB neuroscientist Edward Taub, Ph.D., contributed to a shift in thinking, and in the 1990s he developed constraint-induced (CI) therapy for stroke patients with poorly functioning limbs. As the intensive training helps patients learn to accomplish tasks with their affected limbs, the brain adapts by strengthening communication with those parts of the body. And the results have been remarkable: Most patients see a clinically significant level of improvement in their ability to use their affected limbs, and brain scans have shown an increase in gray matter. Taub and UAB clinical psychologist Gitendra Uswatte, Ph.D., have used CI therapy to help thousands of stroke patientsand adapted it for patients impacted by cerebral palsy, traumatic brain injury, multiple sclerosis, and spinal cord injury. Today CI therapy is in use worldwide.

3

Discoveries on ice

UAB scientists conduct a lot of research in the fieldbut none may go as far afield as James McClintock, Ph.D.; Charles Amsler, Ph.D.; and Maggie Amsler. Their investigations take place at Palmer Station, Antarctica6,898 miles from their campus offices. For two decades, the biologists have led teams that dive into the frigid waters surrounding the icy continent to study the chemical ecology of the unique marine algae and invertebrates living there. What theyve discovered could aid the search for new drugs to help humans. The group also chronicles the dramatic impact of climate change, such as ocean acidification, on Antarctic marine life. You can see climate change happening there like no other place on earth, says McClintock.

4

A pinch of prevention

UAB endocrinologist Constance Pittman, M.D., turned her research passioniodines impact on thyroid functioninto a global mission. In the 1990s and 2000s, she teamed up with Kiwanis International and UNICEF to help eradicate iodine deficiency disorders (IDD), a prevalent cause of cognitive disabilities. Pittman traveled the world to convince companies to add iodine to table saltthe simplest solution for preventing IDD. And her work helped make a lasting impact.

5

Target: Diabetes

In 1973, UAB opened the nations first public diabetes hospitaland the first linked with an academic medical center. Today physicians on the front lines of the diabetes epidemic have an exciting new option to help their patients, thanks to breakthrough research from UABs Comprehensive Diabetes Center.

6

Sharing stories that matter

WBHM 90.3 FM radio went on the air in 1976 as the 200th National Public Radio (NPR)-affiliated station. A member-supported service of UAB, WBHM provides global news and award-winning local coverage to Birmingham and the surrounding region. The station also recently welcomed StoryCorps, an NPR-affiliated initiative, to collect stories from the Birmingham community that will be housed at the Library of Congress in Washington, D.C.

7

Book of Life

Its tough to find a physician anywhere in the world who hasnt learned a few things from Tinsley Harrison, M.D. The legendary School of Medicine cardiologist and dean created and edited Harrisons Principles of Internal Medicine, which has been reprinted 20 times, translated into 14 languages, and become arguably the most recognized book in all of medicine, according to the Journal of the American Medical Association.

8

Foresight

The School of Optometry has been a pioneer since it opened in 1969 as the nations first optometry school associated with an academic medical center. Three years later, it became the first optometry teaching program affiliated with a Veterans Administration (VA) hospital, establishing a national model. Today more than 2,500 optometry staff and students from various schools work in the VA system nationwide.

9

Helping our hometown

Living and working in the heart of the city, UAB students, faculty, and staff cant help but feel a connection to Birmingham. Here are just a few ways Blazers have volunteered to support their neighbors:

10

A whole new ball game

Gene Bartow Mens basketball coach1977-1996

UAB started a winning tradition in 1977 when it hired coach Gene Bartow away from powerhouse UCLA to start a mens basketball program. He created a legendary team able to topple top rivals and reach the NCAA Tournament in just its third seasonthe first of 15 NCAA Tournament and 12 National Invitational Tournament appearances on its record. As UABs first athletic director, Bartow also helped UAB compete in other arenas. Today student-athletes in 18 sports give Birmingham reasons to cheer. Take a spin through some of the Blazers most memorable moments:

11

New views of history

Its as if Indiana Jones and Google Earth had a love child. Thats how UAB anthropology faculty member and National Geographic fellow Sarah Parcak, Ph.D., described space archaeology to Stephen Colbert on The Late Show in 2016. She has pioneered the use of high-resolution satellite imagery to search for the buried remains of lost civilizations. And her discoveries have thrilled people worldwide, including Colbert. She was even mentioned in a Jeopardy! answer earlier this year.

12

Defense team

UAB immunologists have been among the first to shed light on the mechanisms powering our bodys defenses:

13

Game changers

Future football helmets may better protect athletes thanks to mechanical engineering professor Dean Sicking, Ph.D. (Before coming to UAB, he developed the lifesaving SAFER barriers used on NASCAR and IndyCar courses.) Analyzing data from thousands of helmet-to-helmet impacts in football, Sicking has developed designs for a new helmet that could address concussionsabsorbing as much energy of the impact as possible so that the athlete has less risk of brain injury.

14

The dividends of discovery

In 2018-2019, UAB received $602 million in research grants and awardsjust one year after surpassing the $500-million milestone for the first time. We are aiming high and exceeding our goals, and it is a testament to the UAB research communitys great ideas, hard work, and will to succeed, says Christopher Brown, Ph.D., vice president for research. A rise in research funding means more opportunities to explore the frontiers of knowledgebut it also enables UAB to attract top minds from around the country in health care, engineering, the sciences, and more, plus create new jobs that boost the local economy. Want to ensure that UAB continues its upward trajectory? Philanthropic support helps position the university to attain competitive research grants.

15

Giant leaps

Space is the place for UAB people and technology:

Researcher Larry DeLucas, O.D., Ph.D., became the first optometrist in orbit with a 1992 mission aboard the shuttle Columbia. There he conducted experiments to grow protein crystals, which give scientists a 3D view of protein structuresand a greater understanding of the roles they play in disease. DeLucas also served as chief scientist for the International Space Station in 1994-1995.

Astrophysicist Thomas Wdowiak, Ph.D., passed away in 2013, but his name lives onon Mars. The Red Planets Wdowiak Ridge honors the physics faculty members role in NASAs Mars Exploration Project. Wdowiak was in charge of operating the Mossbauer spectrometers onboard the Spirit and Opportunity rovers that helped uncover firm evidence that water once existed on Mars.

16

Focus on finances

Would you like to get better at saving, budgeting, or investing? Or do you dream of launching a business? The Regions Institute for Financial Education in the Collat School of Business has been helping people throughout the community develop practical, lifelong financial management skills since 2015. Some of its programs include a Money Math Camp for middle schoolers, a College Bridge Camp to prepare high schoolers for life after graduation, and for adults, a Do-It-Yourself Credit Repair Workshop.

17

Going green

Campus expansions have reshaped Birminghams Southside, and UAB works hard to be a good steward of that spaceand set a sustainable example. In 2008, UAB brought open green space into the heart of Birmingham by converting a city street into the Campus Green. Now UAB is aiming to reduce its greenhouse gas emissions by 20 percent and establish a clean energy standard of 20-percent renewable energy by 2025.

18

Ingenuity vs. Infection

Virus vanguards

Antiviral therapies are essential for treating everything from influenza to HIV. In 1977, UAB pediatrics experts Richard Whitley, M.D., and Charles Alford, M.D., helped spark the antiviral revolution by developing vidarabine, the first drug to treat encephalitis caused by the herpes simplex virus. In the 1990s, Whitley and his team transformed the herpes virus into a genetically engineered weapon against tumors.

Vaccines for everyone

The laboratory of Moon Nahm, M.D., is a national treasure, notes the National Institutes of Health. But its discoveries could help protect millions of children worldwide threatened by S. pneumoniae infections, the leading cause of pneumonia. (Nahms lab also is designated a World Health Organization Pneumococcal Reference Laboratory.) His mission is to make pneumonia vaccines more affordable for use in developing countries.

Global guardian

GeoSentinel is a worldwide network of clinics watching for potential pandemics in an increasingly interconnected world, ready to relay information quickly about new disease outbreaks and effective treatments. And it has Alabama roots. UAB travel medicine expert David Freedman, M.D., cofounded GeoSentinel, a collaboration between the International Society for Travel Medicine and the Centers for Disease Control and Prevention, in the 1990s. He also directed the network for 20 years.

19

Staying safe on the road

In 2002, UAB public health researchers unveiled the Digital Childa pioneering computer model evaluating the physical consequences of car crashes on young passengers at various stages of developmentto generate data that could lead to improved child safety devices. Shift gears to today, and researchers in UABs TRIP (Translational Research for Injury Prevention) Lab use virtual realitya first-of-its-kind SUV simulator built with Honda Manufacturing of Alabamato study distracted driving in an effort to save lives. The TRIP Lab also has a portable simulator for schools and community events to help educate students and others on the dangers of distracted driving.

20

A home for Birmingham history

Odessa WoolfolkEducator and civic leader

When Birmingham first dreamed of developing a civil rights museum and research center, UABs Odessa Woolfolk, then special assistant to the president and director of community relations, and Horace Huntley, Ph.D., a historian and first director of the African American studies program, helped lead efforts to turn that idea into a reality. The Birmingham Civil Rights Institute opened in 1992, with Woolfolk as president of its board of directors. Huntley also directed the institutes Oral History Project, which preserves the accounts of foot soldiers and other witnesses to the Birmingham campaign. Today the BCRI attracts visitors from around the world and is a key component of the Birmingham Civil Rights National Monument.

21

Invention in action

Faculty, staff, and students are designing the future for the rest of us. Preview some of their ingenious solutions:

Each year, biomedical engineering and business students develop technologies to help people overcome physical limitations. Examples include a joystick-controlled wheelchair for toddlerswhich won an international awardbuilt for the Bell Center for Early Intervention Programs, and a special scale to help wheelchair users monitor their weight, used by the Lakeshore Foundation. Another design, a mechanical umbrella to protect power wheelchair users from rainy weather, scored second place at the 2018 World Congress on Biomechanics.

Graphic design students in UABs Bloom Studio unleash their talents to support local nonprofits and underserved communities. You can spot their work on license plates and signs that promote and protect the Cahaba Riverpart of a collaboration with the Cahaba River Society.

Solution Studios pairs Honors College, engineering, and nursing students with UAB health professionals to tackle everyday problems affecting patient care. One team has designed a device prototype that could improve quality of life for patients wearing ostomy bags to expel waste. Another has focused on new, more comfortable methods of applying wires to the skin in settings such as intensive care units.

22

Spreading the word

Low literacy levels translate into increased high school dropout rates, a lower-performing workforce, and higher rates of social problems, say UAB School of Education experts. For years UABs Maryann Manning, Ed.D., led the charge to improve literacy across Alabama, launching programs such as a conference that attracted thousands of local schoolchildren to share their writing with authors and illustrators. Today the Maryann Manning Family Literacy Center continues her legacy, providing enrichment activities in reading, writing, math, arts, and science for children and helping teachers across Alabama learn innovative strategies to foster literacy skills in their classrooms.

23

The heart of innovation

John Kirklin, M.D.Surgery superstar

John Kirklin, M.D., helped put Birmingham on the medical map when he was recruited in 1966 to chair the Department of Surgery. He already was a superstar at the Mayo Clinic, where he had revolutionized cardiovascular surgery by improving the heart-lung machine and performing the first operations for a variety of congenital heart malformations. At UAB he continued to pursue new methods and techniques, such as the development of a computerized intensive care unit with continuous monitoring of vital functions, which became a model for ICUs worldwide.

When Kirklin passed away in 2004, colleagues estimated his medical innovations had saved millions of lives. And his legacy thrives in other ways: UAB is a world-class medical center in part because of Kirklins work behind the scenes, where he championed the combination of public and private investments to foster growth. His textbook, Cardiac Surgery, remains a must-read for anyone in the field. His name lives on in The Kirklin Clinic of UAB Hospital, which opened in 1992. And his son, cardiothoracic surgeon James Kirklin, M.D., directs UABs James and John Kirklin Institute for Research in Surgical Outcomes.

24

Birthplace of new businesses

UABs ideas and energy are an engine for entrepreneurship. The university was a founder of Birminghams Innovation Depot, where start-up companiessome born from UAB research breakthroughsfind the resources they need to grow. Today Innovation Depot is the Southeasts largest high-tech business incubator, home to more than 100 companies.

25

University of opportunity

In the fall of 2019, underrepresented students made up nearly 42 percent of UABs enrollment, and 20.5 percent of undergraduates were first-generation students. UAB has a long history of widening access to higher educationand potential careers in science and health careamong diverse students. Back in 1978, the Minority High School Research Apprentice Program began matching local students with faculty members for summer research experiences. Today, initiatives such as the Department of Surgerys Pre-College Internship for Students from Minority Backgrounds and the Neuroscience Roadmap Scholars program offer similar opportunities for students along their educational journeys.

26

Successful careers begin here

More than 135,000 alumni call UAB their alma mater. Today youll find them across the United States and around the world, working as leaders in health care, science, business, art, engineering, government, education, and other fields. Many stay connected with UAB through the National Alumni Society, which was established in 1979 and has 63 chapters in locations ranging from Washington, D.C., to Taiwan.

27

Read the original here:
UAB: 50 years of Improving Birmingham, Alabama and the World - Birmingham Times

Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Science…

Global Parkinsons Disease Treatment Market 2020-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Get Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

Read more:
Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Science...

What can hold back the hands of time? Scientists have looked at these five treatments – Ottawa Citizen

Scientists have been researching ways to increase a humans healthspan and possible lifespan for decades. Here are things they have considered, and what they have learned.

The intervention:Rapamycin

What is it? First identified in the 1970s in a soil sample from Easter Island, this FDA-approved drug is used to suppress the immune system in transplant patients. Counterintuitively, it also appears to boost immune function in healthy animals. Rapamycin may reduce inflammation, which increases with age. One study found that rapamycin rejuvenated the hearts of old mice. After treatment, there were significant improvements to cardiac function. Research with mice has also found that even when they where administered rapamycin late in life, the mice still had improvements to lifespan and their healthspan.

The verdict: Geroscientist Matt Kaeberlein said rapamycin shows the most promise of any drug that targets aging, in his opinion, although he doesnt necessarily think rapamycin will increase lifespan by 20 to 30 years on average in people. Although it might at the right dose. I do think theres reason to believe that rapamycin could improve several age-related health problems, including boosting immune function and protecting against dementia, cancers, and heart disease.

But critics say it is unclear what the downstream effects could be. If you take a compound like that for a few decades, there may be downstream effect a small epidemic of lymphoma, perhaps, said geriatrician Dr. Peter Boling. While it is approved to prevent rejection in organ transplant patients, it is not approved to treat aging.

There are also questions about side effects, which may include susceptibility to infection and the possibility of developing lymphoma.

We still dont know about all of the hidden dangers. As hopeful as we might be, we have to be aware of the limitations, said Boling.

The intervention: Metformin

What is it? This drug has been prescribed to millions of people to treat diabetes. Among other effects, it decreases insulin levels. It also appears to target biological mechanisms related to aging. Its anti-aging effects may be linked to its influences on metabolic and cellular processes associated with inflammation. It has been linked to lifespan extension and protection against age-related diseases in animal models.

The verdict: The speculation in scientific circles has been that many of the drugs used to treat early-stage chronic disease may be effective, at least in part, because they target aging itself.

Metformin is an interesting case, said Kaeberlein. It clearly increases survival in people with diabetes and likely would do the same for pre-diabetics and others with significant metabolic disease, which represents a growing percentage of adults, he said. However, its less clear whether metformin will be beneficial in people who are metabolically healthy and exercise regularly.

The studies in mice suggest that metformin is different from rapamycin, in the sense that metformin only increases lifespan by a very small amount and in some cases has been reported to have no effect or even shortens lifespan in mice.

The FDA has accepted a clinical trial, Targeting Aging with Metformin, known as TAME, which will test whether metformin can delay the onset of age-related diseases and conditions including cancer, cardiovascular disease and Alzheimers disease. The goal of the trial, which is estimated to cost $55 million, is not to help people live to be 120 years old but to add health to our years, said the American Federation for Aging Research.

Like metformin, several promising drugs show great potential and await trials. If successful, the TAME trial would give the pharmaceutical industry impetus to advance these drugs and transform aging from a period of sickness to a time of extended vitality.

The intervention: Caloric restriction

What is it? A dietary regimen that reduces calories while maintaining nutrients. Research in lab animals, which started almost a century ago, has shown that it is possible to delay age-related diseases in mice and rats through dietary and caloric restriction, but results have varied.

A parallel study of two groups of rhesus monkeys, one at the University of Wisconsin and the other at the U.S. National Institute on Aging, looked at the life-prolonging and health effects of a calorie-restricted diet. The researchers found that the Wisconsin monkeys on a diet with 30 per cent fewer calories than the control group survived to about 28 years for males and about 30 years for females a couple of years above average for monkeys in captivity. Calorie-restricted monkeys in both groups showed fewer age-related health conditions compared to the control monkeys.

Some biohackers people who use biological interventions to optimize health have embarked on caloric restriction diets, with the goal of living longer. Entrepreneur Dave Asprey, author of Bulletproof Diet, has said he plans to live to be 180 and is hacking his own biology with a number of interventions, including supplements and a strict diet.

The verdict so far: The rhesus monkey study also produced some contradictory findings. The National Institute on Agings study found that while the dieting monkeys showed improved health, they didnt necessarily live longer than the control monkeys. Its not clear why there was a difference between the two groups of monkeys, although they were fed different diets and had different feeding times and access to food. The ages at which they dieted may also have come into play.

There is no compelling evidence caloric restriction will work with people, said Doug Gray, a molecular biologist with an interest in the role of protein homeostasis in aging and diseases of aging at the Ottawa Hospital Research Institute.

If this sounds like a depressing route to extreme longevity, even scientists agree. Noted one researcher: Life might seem longer, but it wouldnt necessarily be longer.

The intervention: Gene editing

What is it? Genome editing, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced.

Last February, for example, the journal Nature Medicine reported on a therapy using CRISPR-Cas9 genome editing technology aimed at suppressing rapid aging in mice with the rare genetic disorder progeria, which causes accelerated aging. According to the report, two months after the therapy, the progeria mice were stronger and more active and had better heart health. Their lifespan also increased by about 25 per cent.

The verdict so far: Not ready for prime time, said Boling. Even though we have successfully mapped the human genome, and its technically possible to remove a gene sequence and replace it, we have yet to successfully edit genes in a complex organism. Many people dont want to eat food containing genetically-modified organisms, let alone become one, he said.

I dont think we have a clear handle on a special gene sequence that would essentially change the aging process. I would want to see if we could do it in a limited and focused way without undue downstream consequences.

In 2017, researchers at Stanford University medical school reported that injections of blood plasma from donors between the ages of 18 and 30 showed promise for helping human Alzheimers patients with mild to moderate symptoms regain some ability to perform basic daily tasks.Colleen De Neve Colleen De Neve / Calgary Herald

The intervention: Young blood

What is it? There have been a number of studies that looked at whether giving old mice blood from young mice could reverse some signs of aging. Even the researchers admitted it sounded creepy, but the results were intriguing. One study at the University of California, Berkeley, published in 2018, found that old mice showed benefits, including better muscle repair, from receiving blood from young mice. But young mice who received old blood had negative effects, including performing poorly on a strength test.

In 2017, researchers at Stanford University medical school reported that injections of blood plasma from donors between the ages of 18 and 30 showed promise for helping human Alzheimers patients with mild to moderate symptoms regain some ability to perform basic daily tasks, such as remembering to take their medications or preparing meals. The results were based on reports from the patients and their caregivers. The researchers cautioned that more research is needed, since the trial involved only nine patients who had received plasma infusions and nine who had received a placebo saline infusion.

The verdict so far: Dont try it. In a statement last February, the FDA said it had significant public health concerns about establishments that offer infusions of plasma from young donors to treat conditions ranging from normal aging and memory loss to Parkinsons disease, multiple sclerosis, Alzheimers disease, and PTSD.

Simply put, were concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies. Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful, warned the FDA. There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials.

Read the original here:
What can hold back the hands of time? Scientists have looked at these five treatments - Ottawa Citizen

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) – Bulletin 99

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South America

Key players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Continued here:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) - Bulletin 99

MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia – P&T Community

NEW YORK and GAINESVILLE, Fla., Jan. 13, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) and AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich's ataxia (FA), today announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio's phase 2 clinical trial of a gene-replacement therapy for the disease.

MVP is MDA's drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular disorders. MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics.

FA is a rare, hereditary disease that causes damage to parts of the spinal cord and brain, and there is currently no cure. AavantiBio was founded with the aim of developing an effective treatment for the disease and improving the lives of FA patients.

"With the approval of several first-time gene-targeting therapies for neuromuscular diseases over the past several years, including the first-ever gene-replacement therapy for spinal muscular atrophy, our community should have much to hope for as more and more therapies continue to be developed," says Lynn O'Connor Vos, MDA's president and CEO. "MDA is thrilled to be a part of the quest to help further develop the first gene-targeting therapy for the treatment of Friedreich's ataxia. By partnering with AavantiBio, together we can address the unmet need faced by patients who live with this genetic disease, for which there are still no treatments and no cures."

Co-founders Manuela Corti, PT, PhD, assistant professor of Pediatrics at the University of Florida, Gainesville, and Barry Byrne, MD, PhD, associate chair of Pediatrics and director of the Powell Gene Therapy Center at UF, started working with the FA community five years ago and are thrilled about their new partnership with MDA.

"This is a great opportunity for AavantiBio, and we're thankful to the MDA for their generous contribution," Dr. Corti says. "We hope to strengthen our collaboration as we work together on this project."

Dr. Corti and Dr. Byrne aim to include both adults and children who have FA in their clinical trials, paving the way for new solutions.

"We're delighted to take the next step in fulfilling our commitment to patients and families living with FA based on this investment from MDA," Dr. Byrne says. "We're looking forward to initiating screening for the first clinical study and a pivotal study in FA before the end of the year. The endorsement and investment from the MDA will be key to our programmatic growth."

MDA's investment will help accelerate AavantiBio's mission and begin production of the clinical gene vector for its therapy program. Clinical trials are expected to begin in 2020.

Dr. Corti was previously awarded an MDA research grant to develop and test a gene-replacement therapy in a mouse model of FA. With the current funding, AavantiBio will sponsor a study at the University of Florida led by Sub Subramony, MD, professor of Neurology. The clinical trial will assess changes in neurological and cardiac function in patients with FA treated with both intravenous (systemic) and intrathecal (into-the-spine) injections of the company's gene-replacement therapy for the mutated FXN gene.

About Friedreich's ataxia

FA is a mitochondrial disease. Mutations in the frataxin gene (FXN) lead to decreased production of the frataxin protein, resulting in diminished energy production in cells, including those of the nervous system and heart. FA's major neurological symptoms include muscle weakness and ataxia, or a loss of balance and coordination. FA mostly affects the spinal cord and the peripheral nervesthat connect the spinal cord to the body's muscles and sensory organs, but it can also affect the cerebellum (causing ataxia) and heart. The prevalence of FA has been estimated at 1 in every 50,000 individuals worldwide. Symptoms typically begin between the ages of 5 and 15 years, and the rate of progression varies from person to person. There currently are no effective cures or treatments for FA.

About AavantiBio

Founded in 2017 and based inGainesville, Fla., AavantiBio is a biotechnology companyfounded on the vision of creating the first effective treatment for FA. The company's gene-replacement therapy approach uses an adeno-associated virus (AAV) vector to deliver a functional copy of the FXN gene to a patient's cells.

The co-founders bring more than 30 years of research experience in the field of neuromuscular disease, including their current work focusing on FA. Dr. Corti has more than 10 years of research experience in gene therapy approaches for the treatment of Duchenne muscular dystrophy and Pompe disease. Dr. Byrne has made significant contributions to theunderstanding and treatment of Pompe disease. He was previously awarded nearly $2 million in MDA funding to conduct foundational research in developing and testing AAV vectors in animal models of muscular dystrophy, and he was the first to show that AAV vectors are able to effectively express therapeutic genes in striated muscle cells.

About the Muscular Dystrophy Association

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to approved, life-changing therapies across multiple neuromuscular diseases. We support the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation's top medical institutions, and each year thousands of children and young adults learn vital life skills and gain independence at MDA Summer Camp and through recreational programs. For more information visitmda.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mda-awards-venture-philanthropy-funding-of-more-than-1m-to-aavantibio-to-develop-gene-targeting-therapy-for-friedreichs-ataxia-300985256.html

SOURCE Muscular Dystrophy Association

Read the rest here:
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia - P&T Community

Oncocyte Announces the Commercial Availability of DetermaRx, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small…

Leonard Cancer Institute at Mission Hospital, California and Florida Precision Oncology sign up as early access sites for the test

Canadian regulatory approval received allowing for path to reimbursement

IRVINE, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the lung cancer care continuum, today announced that DetermaRx, formerly known as the Razor treatment stratification test, is now commercially available in the United States. Additionally, Oncocyte has received regulatory approval in Canada to begin distribution of DetermaRx in that country. DetermaRx enables the identification of early-stage lung cancer patients who may benefit from adjuvant chemotherapy post surgical resection. In a clinical study, high-risk patients identified by this test post-surgery and treated with adjuvant chemotherapy had a significant increase in survival rates.

Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up for early access to the test. The Leonard Cancer Institute at Mission Hospital is a brand new, state of the art regional cancer center and a part of the Providence St. Joseph Health network which consists of 119,000-plus caregivers and employees, serving 51 hospitals and more than 800 clinics delivering a comprehensive range of health and social services across Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Florida Precision Oncology, with locations in Aventura, Miramar and Boca Raton, is focused on delivering multidisciplinary cancer care in the community setting where most cancer is treated.

We are thrilled to officially transform Oncocyte into a commercial-stage company as we make DetermaRx available to lung cancer patients in the U.S., and in the near future, Canada, who are in need of additional clarity when making treatment decisions after surgery, said Ron Andrews, Chief Executive Officer of Oncocyte. Under the current standard of care, approximately 30%-50% of stage I IIA patients who have undergone surgery to remove lung tumors recur and die within five years of surgery. This is unacceptable. We believe DetermaRx, which has been extensively validated and published in top tier peer-reviewed publications, will address this critically underserved treatment decision point, helping physicians and patients make the right treatment decisions at the right time. We are also very pleased that Medicare, which covers ~70% of eligible patients, has proposed positive coverage for this test. This will promote broad access for patients who may stand to benefit from DetermaRx.

Dr. Samer Kanaan, medical director for the lung program at Mission Hospitals Leonard Cancer Institute added, Mission Hospital is honored to have been invited to serve as one of Oncocytes early access partners. This new diagnostic tool will allow us to further enhance our comprehensive lung cancer treatment program and optimize post-surgical treatment decisions. This test serves an important unmet medical need, and I look forward to making it available to patients across the Mission Hospital and Providence St. Joseph networks.

Dr. Edgardo S. Santos, Founding Partner of Florida Precision Oncology, further commented, There is no question that DetermaRx addresses an unmet need in thoracic oncology that we have had for decades. Lung cancer has an incidence of approximately of 225,000 patients per year; if we focus on those adenocarcinoma patients who have stage I and IIA disease, we are talking about 40,000 patients per year with a poor or suboptimal 5-year survival rate. If I have a tool such as DetermaRx which can identify those patients with early pathological stage (supposedly cured) carrying a high-risk for recurrence (based on their genomic profile), there is no question in mind that it will significantly impact the survival of my patients. We also must keep in mind that with the advent of lung cancer screening, we will be able to identify more patients at early stages. Hence, we must be ready to have a discussion regarding therapy post-operatively. Besides poor features from the tumor that we have used for years to decide for or against postoperative chemotherapy, now DetermaRx brings molecular analysis on board which from my standpoint is a kind of personalized management. For example, not all stages IA are the same; some carry higher risk for recurrence than others. We must target them.

Story continues

In bringing DetermaRx to market, Oncocyte will initially prioritize those cancer centers and physicians who manage the highest number of early stage lung cancer patients. Starting the first quarter of 2020, the Company will deploy an experienced salesforce which has a proven track record driving market leadership of novel high-volume molecular diagnostics.

About DetermaRx

DetermaRx is a molecular diagnostic test that enables the identification of early-stage lung cancer patients who may benefit from chemotherapy following surgery, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. The test utilizes a gene expression analysis of 14 specific genes from a patients tumor and a proprietary algorithm to stratify early stage NSCLC patients into one of two groups, one that may benefit from chemotherapy because of high risk of recurrence, and another that may avoid chemotherapy because of low risk of recurrence. DetermaRx is extensively validated and published with independent, blinded global studies in over 1,500 patients and seven publications in prestigious journals including the Lancet and JAMA.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company is currently preparing to launch DetermaRx, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx, the companys liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures.

DetermaDx and DetermaRx are trademarks of Oncocyte Corporation.

Oncocyte Forward Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates and similar expressions) are forward-looking statements. These statements include those pertaining to the time to complete and the results of the Companys ongoing Clinical Validation study for DetermaDx, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the Risk Factors and other cautionary statements found in Oncocytes Securities and Exchange Commission filings, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor ContactBob YedidLifeSci Advisors, LLC646-597-6989bob@lifesciadvisors.com

Media ContactCait Williamson, Ph.D.LifeSci Public Relations, LLC646-751-4366cait@lifescicomms.com

Originally posted here:
Oncocyte Announces the Commercial Availability of DetermaRx, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small...

The Region’s Health Leaders on What’s New and What the Next Decade Will Bring – Business West

Vision 2020

Few industries change as rapidly and as dramatically as the broad, multifaceted realm of healthcare. From oncologists use of cancer fingerprinting and gene therapy to facial transplants for accident victims; from cutting-edge protocols to save the lives of stroke and heart-surgery patients to a dizzying array of new treatments to improve vision the list is seemingly endless, making it impossible to paint a full picture of where healthcare has come in the past decade.

But we at BusinessWest wanted to try anyway and, at the same time, look ahead at what the next decade might bring. So, appropriately, here at the dawn of 2020, we invited a wide range of healthcare professionals to tell us what has been the most notable evolution in their field of practice in the past 10 years, and what they expect or hope will be the most significant development to come in the next decade.

The answers were candid, thoughtful, sometimes surprising, but mostly hopeful. Despite the many challenges healthcare faces in these times of advancing technology, growing cost concerns, and demographic shifts, the main thread is still innovation smart people working on solutions that help more people access better care. After all, healthcare is, at its core, about improving peoples lives, even when they seek it out during their direst moments.

Innovation and promise. Thats what we believe a new decade will bring to all corners of the healthcare world that is, if these leaders, and countless others like them, have anything to say about it.

Joanne Marqusee

President and CEO, Cooley Dickinson Health Care

Joanne Marqusee

The most significant recent development in healthcare administration has been a recognition of the role patients play in their own healthcare. Crossing the Quality Chasm: A New Health System for the 21st Century, published in 2001 by the Institute for Healthcare Improvement, called for a massive redesign of the American healthcare system. Specifically, it provided Six Aims for Improvement, five of which focused on safety, effectiveness, timeliness, efficiency, and equity. Not talked about as much, the sixth aim was to make healthcare patient-centered.

While we still have a ways to go to truly be patient-centered, we have witnessed a sea change in the past decade in this regard. Patients are increasingly active participants in their care, questioning their doctors and other providers to ensure that they understand their options, using electronic medical records to engage in their care, and speaking out about what they want from treatment or forgoing treatment at the end of life. The best healthcare providers both organizations and individuals embrace these changes, welcoming patients as more than recipients of care, but rather active partners in their own care and decision making.

My hope for the most significant development over the next decade has to do with providing universal healthcare coverage while controlling healthcare costs. While we almost have universal coverage in Massachusetts, too much of the nation does not. A hotly debated topic, universal healthcare has many benefits, including increasing access to preventive and routine medical care, improving health outcomes, and decreasing health inequalities.

Dr. Nicholas Jabbour

Chairman, Department of Surgery, Baystate Medical Center

Dr. Nicholas Jabbour

The most significant development in surgery over the past decade has been the move toward less invasive surgical approaches made possible through advanced technology. These approaches include robotic and minimally invasive surgery, including intraluminal surgery in areas such as gastroenterology, cardiology, and neurosurgery for exemple, the passage of an inflatable catheter along the channel inside of a blood vessel to enable the insertion of a heart valve instead of making a large opening in the chest. As a result, we have seen a big shift from inpatient to outpatient surgery with shorter hospital stays and improved post-op recovery.

In the next decade, we foresee these innovations in less invasive surgery will be enhanced by better computing and software integration. This interaction will include the merging of radiological and potentially pathological information which is currently available in a digital format with real-time visualization of anatomical structure during surgery. This will offer surgeons the opportunity to improve the accuracy and speed of a surgical procedure while minimizing the risks.

The next decade will also see major innovation in the area of transplantation with the development of tissues or whole organs through bio-engineering manipulation of animal or a patients own cells. The integration of this bio-engineering manipulation with currently available technology, such as 3D printing and 3D imaging, will provide patients with the needed tissue or organ including valves, bone grafts, hernia mesh, skin, livers, and kidneys in a timely manner. This development will revolutionize the field of transplantation and surgery in general.

Karin Jeffers

President & CEO, Clinical & Support Options Inc.

Karin Jeffers

Over the past 10 years, weve seen a growing adoption within the behavioral-health and medical fields of holistic treatment models. While the two disciplines were once treated as different animals, the entire health field is now moving to treat both the body and the mind together. The next 10 years are likely to bring these two fields even closer.

Today, youre seeing behavioral-health clinicians being hired into physical health practices. Likewise, physical health providers are cross-training to better understand behavioral issues. Whereas, a decade ago, a behavioral-health client might be assigned a therapist or a psychiatrist, they are now gaining access to more robust set of supports, including nursing, case management, recovery coaching, and peer support from those with lived experience. Government mandates and payment model changes are forcing outcomes-based integration, too. Pediatricians, for example, must now do behavioral-health screenings of all youth under 21. In the mental-health space, youre seeing clinicians ask about weight, exercise, and other physical factors.

Were seeing significant movement on both the state and federal levels to value outcomes over volume. Its reflected in the criteria set by the Excellence in Mental Health Act for certified community behavioral-health clinics, a designation CSO has earned, and in the work we have done with the Substance Abuse and Mental Health Services Administration. Our ability to tailor programs, like our grant-funded work at the Friends of the Homeless shelter in Springfield, has literally saved lives among those experiencing homelessness and co-occurring conditions, like substance-use disorders.

In the coming years, we hope to see integrated care models become even more mainstream. Things appear headed in the right direction, but government action establishing payment reform within the behavioral-health field needs to be taken and the integrated models need to be appropriately funded. Such changes would affirm overall health and wellness to include both physical and behavioral health.

Dr. Yannis Raftopoulos

Director, Holyoke Medical Center Weight Management Program

Dr. Yannis Raftopoulos

Weight management is a rapidly evolving field, and I am fortunate to be part of it. One of the most significant innovations this field has experienced in the last 10 years was the development of a new gastric balloon. Packaged in a small capsule and swallowed with water, the Elipse balloon provides satiety while requiring no procedure or anesthesia for its placement and removal. Together with its excellent safety profile, the Elipse balloon is the least invasive and yet effective weight-loss modality available today. Elipse is manufactured in Massachusetts by Allurion Technologies.

I had the opportunity to be an investigator in the European trial which led to the Elipse market approval in the European Union in 2016. Recently, Holyoke Medical Center was among 10 U.S. sites in which an FDA-regulated trial was conducted. The trial was completed successfully, and Allurion has submitted data requesting FDA approval to market Elipse in the U.S. The balloons use in Europe shows that patients can lose more than one-fifth of their initial weight.

A New England Journal of Medicine study reported that 107.7 million children and 603.7 million adults, among 195 countries, were obese in 2015. High body-mass index accounted for 4 million deaths and contributed to 120 million disability-adjusted life-years. Obesity is a chronic disease, and its management requires long-term guidance and close patient-physician communication. Successful collaborations between existing best practices with technology innovations that will allow delivery of effective weight-management care on a massive and global scale could be the most significant evolution in the field in the next 10 years.

Dr. Hong-Yiou Lin

Radiation Oncologist, Mercy Medical Center

Dr. Hong-Yiou Lin

The advent of new medical oncology drugs has improved control of microscopic and, to a lesser extent, macroscopic disease, allowing local treatments, such as surgery or radiotherapy, to increase survival. To cure cancer, we need to eliminate cancer cells where they started, as well as any microscopic cells traveling through the body. The idea of using immunotherapy to fight cancer has been around for decades, but bringing this idea to the clinic has been hampered by the cleverness of cancer cells knowing how to evade detection by our immune system. Recently FDA-approved immunotherapy either takes away that invisibility cloak or wakes up our dormant immune cells to start fighting cancer.

The biggest development in oncology in the next 10 years will be personalized precision medicine, which allows the oncology team to tailor treatment to each patients unique cancer biology and life circumstances. Meanwhile, improvements in cancer diagnosis will come from novel PET radiotracers and new MRI sequences that allow for more accurate staging and identification of the best site to biopsy. Pathologists will use novel tools such as genome sequencing to supplement traditional microscopy to subclassify the specific type of cancer within a certain diagnosis instead of grouping into broad categories.

Surgical, medical, and radiation oncologists can then use the above information to decide on the best sequencing between surgery, systemic therapy, and radiotherapy to minimize side effects and maximize cure. Medical oncologists will be able to offer more drugs that target new mutations, overcome drug resistance, increase specificity to a mutation, or better fine-tune immunotherapy, targeting only cancer cells by enlisting gene modification as well as natural killer cells. Radiation oncologists will have new radiomic and genomic tools to personalize the radiation dose and volume, and when to offer radiotherapy.

In short, over the next 10 years, cancer care will continue to move away from the traditional one-size-fits-all model toward a more personalized approach.

Dr. Jonathan Bayuk

Medical Director, Allergy & Immunology Associates of New England

Dr. Jonathan Bayuk

There have been incredible and exciting advances in allergy and immunology in the last two years. However, the unmet needs of allergic and autoimmune-disease-afflicted patients has grown dramatically in the last 20 years. In response to the increasing prevalence and acuity of allergic diseases and autoimmune diseases, the world has launched products to help address these very severe patients. These medications are indicated for many conditions and work very well. They are generally safe, but are very expensive. These medicines are different than traditional pharmaceutical drugs as they are not chemicals, but biologically derived medicines designed to augment or modify the immune response. As such, they are call biologic medications.

In the field of allergy and immunology, we can now dramatically treat and potentially cure many diseases that in the past were very challenging to manage. The biologic medicines that we have now treat asthma, eczema, allergic disease, and hives. The patient selection is based on severity of their condition, and these medicines are only for moderately to severely affected people. If, as a medical profession, we were to place as many people as possible on these therapies, the cost would be astronomical and not sustainable.

However, is it fair to deny any of these patients access to these treatments who truly need them? I would argue that choice is a very difficult one to make, and as physicians, our primary goal is healing at whatever cost. As a nation, we have a dilemma. Can we afford the medicines we have or not? It is unclear that any serious legislative body is willing to tackle that question. For now, the use of these medicines is changing lives dramatically, and it is an exciting time to be able to use these newer tools to help our patients live better lives.

Dr. David Momnie

Owner, Chicopee Eye Care

Dr. David Momnie

What are the most significant advancements in eye care in the last decade? It depends on whom you ask. Retinal ophthalmologists would probably say its the treatment of wet macular degeneration, a leading cause of blindness, with anti-VEGF injections. Cataract surgeons would most likely cite small-incision surgery and new lens implants that often leave patients with 20/20 vision. Glaucoma specialists might tell you its the development of MIGS, or minimally invasive glaucoma surgery. These operations to lower the pressure in the eye use miniature devices and significantly reduce the complication rate.

Primary-care optometrists and ophthalmologists would no doubt talk about the advances in optical coherence tomography, a remarkable instrument using light waves that gives cross-sectional pictures of the retina. The technique is painless and non-invasive and is becoming the gold standard in eye care because it has revolutionized the diagnosis and treatment of glaucoma and macular degeneration. For optometrists specializing in contact lenses, using newly designed scleral lenses to restore vision in people with a corneal disease called keratoconus has been a major development. There are many other specialists in eye care, including LASIK surgeons, that have seen remarkable changes in technology.

What will the next decade bring? Artificial intelligence (AI) is becoming more accurate for screening, diagnosing, and treating eye conditions. AI systems can increasingly distinguish normal from abnormal pictures of the retina. Where there is a shortage of ophthalmologists and optometrists, AI screenings combined with telemedicine, providing remote care using communications technology, may be able to find and treat more people who are falling between the cracks of our healthcare system. The term 20/20 is the most common designation in eye care, and the year 2020 will probably usher in another decade of remarkable developments in our field.

Teresa Grogan

Chief Information Officer, VertitechIT

Teresa Grogan

From the perspective of technology that enables healthcare, the biggest game changer of the last decade has been the iPhone and now, essentially any smartphone.

Steve Jobs introduced the first iPhone in 2007 (a little over a decade ago), and physicians embraced it quickly. It started as a simple tool for doctors (applications like the PDR, or Physicians Desk Reference) for looking up drug interactions. Today, its a portable EMR, a virtual visit facilitator, and a remote-monitoring device for many healthcare providers, as many patients have embraced and insisted on this technology to improve access to care. As the cost decreases and cellular bandwidth improves, the rapid growth of the IoMT (Internet of Medical Things) will place smartphones at the center of the next wave of healthcare technology breakthroughs.

Looking forward, Id like to see complete elimination of passwords to access electronic information. While there has been some movement toward this with tap and go badges and fingerprint readers, a single standard is needed that would work regardless of the software program used. I hope there are greater strides in the creation, deployment, and adoption of other biometric technologies, like iris, face, or voice recognition, so that a healthcare professional could walk into a patient room or into a hospital and the computer systems would know his or her identity in immediate and secure fashion. If access to the data needed by a healthcare provider were as easy as turning on a light switch, the improvements in quality of life and efficiency in work for that provider would translate to improved patient outcomes.

Dr. Aaron Kugelmass

Vice President and Medical Director, Heart and Vascular Program, Baystate Health

Dr. Aaron Kugelmass

We have seen many improvements in cardiovascular care over the last 10 years, but the development, approval for clinical use, and dissemination of transcutaneous aortic valve replacement (TAVR) stands out as the most dramatic. This new technique allows cardiologists and cardiac surgeons, working together, to replace the aortic valve without opening a patients chest or utilizing heart-lung bypass, which has been the standard for decades. This less invasive approach is typically performed under X-ray guidance and involves accessing a blood vessel in the leg and guiding a catheter to the heart.

The TAVR procedure was first approved for clinical use in November 2011. It was initially limited to very sick patients, who were not candidates for traditional surgery because of the risk it posed to them. TAVR allowed patients who otherwise could not receive life-saving valve surgery to have their valves replaced with improvement in longevity. With time and experience, the procedure was approved for lower-risk patients as well, and more recently has been approved for the majority of patients, including those with low operative risk. TAVR has been shown to be equivalent or safer than traditional aortic valve-replacement surgery, and is quickly becoming the procedure of choice for most patients who require an aortic valve replacement. Since the procedure typically does not require open-heart surgery, recovery time is much shorter, with some patients going home within a day or two.

In the next 10 years, we expect that similar less-invasive procedures with shorter recovery time will be developed for other heart-valve conditions in patients who otherwise could not receive therapy.

Beth Cardillo

Certified Dementia Practitioner and Executive Director, Armbrook Village

Beth Cardillo

During the last 10 years, neuroscientists have been researching the causes of Alzheimers disease. There has been much discussion about which comes first the amyloid plaque or the fibrillary tangles that develop in the brain, which are roadblocks to cognition, thus causing the difficulties with Alzheimers and other related dementia. That question has not been answered yet. Researchers were able to isolate the APOE gene, which is a mutant gene that is found in familial Alzheimers disease, helping us to better diagnose it. We have also better understood how diet, exercising both body and brain, and lifestyle contribute to the disease. Currently there are 101 types of dementia, with Alzheimers accounting for 75% of cases.

The next 10 years will result in more preventive actions. One major action will be to help people avoid developing type 2 diabetes, which may be labeled the next cause of Alzheimers (this type of Alzheimers is already being called type 3 diabetes). There has been a major link between sugar in the hippocampus and Alzheimers disease. Though there is no cure yet for Alzheimers, we are finding more information based on genetics, diet, and PET scans, which can show shrinkage in the brain.

Every year, researchers are more hopeful that a new drug will be developed to eradicate the disease. The last new drug from Biogen was looking hopeful in clinical trials, but that turned out to be not the case. Prevention continues to be at the forefront, as well as participating in clinical trials. More people who do not have dementia or mild cognitive impairment are desperately needed for clinical trials so comparisons of the brain can be made.

Ellen Furman

Director of Nursing, American International College

Ellen Furman

As in all healthcare, the one thing that can be ascertained is constant change. The same can be said in nursing education today. No longer is the instructor-led lecture method of teaching considered best practice in education, but rather the shift to using class time to apply learned concepts. One way this is done is through the flipped classroom. Using this educational modality, students study the concepts being taught preceding the class, followed by class time where students apply these concepts in an interactive activity, thereby developing students abilities to think critically, reason, and make healthcare judgements based upon the application of knowledge.

Another change in nursing education is an expanded focus away from pure inpatient (hospital-based) clinical education to outpatient (community-based) clinical education. While hospital-based education remains essential, the realization that most healthcare provided is in outpatient settings has broadened the clinical experiences required to prepare the graduate registered nurse for care provision.

Additionally, with healthcare as complex as it is, nursing students are being taught to be prepared for entry into practice. Education regarding the use of evidence-based practice, how to apply for the licensure examination, preparation to be successful on the National Certification Licensure Exam, nurse residency opportunities, interviewing techniques, transitioning from student nurse to registered nurse, etc. are all taught using a variety of educational modalities based upon the current best available evidence in nursing education.

As we forge ahead in healthcare, nurse educators will continue to evolve to meet healthcare needs through the education of nursing students so as to prepare them to provide care to meet the needs of those we serve well into the future.

James Haas

Co-owner, Orthotics & Prosthetics Labs Inc.

James Haas

Advances in prosthetic technology have clearly been the most significant development in my field over the past decade. From knees and feet that adapt to different walking speeds and terrains to hands that send sensations of touch to the brain, every aspect of patient care has changed and continues to change at a rapid pace.

Prosthetic feet, knees, and sockets have been greatly impacted. Once made from multi-durometer foams and wood, the prosthetic feet of today are made from carbon, fiberglass, and kevlar laminated with modified epoxy resins. They store energy and adjust to uneven terrain and hills. Microprocessor knees have on-board sensors that detect movement and timing and then adjust a fluid/air control cylinder accordingly. These knees not only make it safer for a person to walk, they also lower the amount of effort amputees must use, resulting in a more natural gait. Sockets once made from stiff materials are now incorporated with soothing gels and flexible adjustable systems that allow a patient to make their own adjustments to improve their comfort.

As for the next decade, I hope to see national insurance fairness. Devices typically last about three to five years. Some people make them last longer, but others, especially growing children, need replacements more often. Many private insurance plans have annual caps and lifetime limits on coverage for orthotics and prosthetics. The Amputee Coalition of America authored insurance-fairness legislation and has lobbied for its implementation for over a decade. This legislation has been ratified in 20 states, including Massachusetts. The Fairness Act requires all insurance policies within the state to provide coverage for prosthetics and orthotics equal to or better than the federal Medicare program and have no coverage caps and lifetime restrictions.

Dr. Lisa Emirzian

Co-owner, EMA Dental

Dr. Lisa Emirzian

The most significant development in the field of dentistry over the past decade has been the integration of digital technology into our daily practices. There are three components of digital dentistry: data acquisition, digital planning, and, finally, the manufacturing of the restoration to be created. Data acquisition today is accomplished with digital radiographs, paperless charting, intra-oral scanners, cone-beam 3D scanners, and video imaging. For the planning process, we now have the ability to merge the data with software that enables computer-aided design and digital smile design, allowing dentists to perform complex procedures, including guided surgical treatments and smile designs, with optimum results. Fabrication and execution of the final restorations can be done in the office or, more often, in laboratories with highly sophisticated digital milling machines, stereolithography, and 3D printing.

In the next decade, we will see data fusion to ultimately create the virtual patient. The next-generation digital workflow will merge intra-oral 3D data with 3D dynamic facial scans, allowing dentists to create 3D smile designs and engineer the dentofacial rehabilitation. The integration of scanners and software will expedite the delivery of teeth in a day. In addition, multi-functional intra-oral scanners will allow for early detection of carious lesions and determine risk levels for different patients.

Above and beyond this foreseeable future, artificial intelligence (AI) will be the next paradigm shift. Companies are already looking for big-data collection and deep machine learning to help the practitioner in their everyday chores of diagnosis and treatment. AI cloud-based design platforms will input data, and AI engines in the background will aid in all parts of dental treatment, including diagnosis, design, and fabrication of final restoration.

Let us not forget one thing: the future is all about us people utilizing technology to enhance the human connection between doctor and patient.

John Hunt

CEO, Encompass Health Rehabilitation Hospital of Western Massachusetts

John Hunt

A significant rehabilitation development from the past includes one that may surprise you. Time. A luxury we once knew, time meant patients could recover in a hospital longer after a surgery, an accident, or an illness. Nurses had more time to assess patients to know exactly what they needed. Insurance companies approved longer patient stays through lengthy consideration. Ten years ago, a stroke survivor could recover for two weeks in a hospital and then join us for a rehabilitation stay that would last several weeks.

Today, a three- to five-day stay in the referring hospital, followed by a two-week stay in rehabilitation, is the norm. We are seeing significant decreases in the age of stroke survivors as well as an increase in the number patients who survive with cognitive and physical disabilities. Yet, we also see medical breakthroughs, including the discovery of tissue plasminogen activator (TPA) nothing short of a miracle. TPA actually reverses the effects of an evolving stroke in patients when used early on, making recoveries easier.

With new advanced technologies being introduced every year, rehabilitation continues to progress at a rapid speed. Looking into the future, evidence-based research will continue to grow to help us make knowledgeable decisions that ultimately impact patient outcomes. Increased clinical expertise will lead to higher functional gains in shorter amounts of time. As a result, acute inpatient rehabilitation will impact the lives of patients like weve never seen before.

Dr. Susan Bankoski Chunyk

Doctor of Audiology, Hampden Hearing Center

Dr. Susan Bankoski Chunyk

The most common treatment for hearing loss is hearing aids. Although digital processing has been available in hearing aids since 1996, the past 10 years have offered great leaps in technology for people with hearing loss. Each generation of computer chip provides faster and smarter processing of sound. Artificial intelligence allows the hearing-aid chip to adjust automatically as the listening environment changes, control acoustic feedback, and provide the best speech signal possible. People enjoy the convenience of current hearing aids Bluetooth streaming, smartphone apps, and rechargeable batteries.

These features are the icing on the cake, but the real cake is preservation of the speech signal, even in challenging listening situations. Since the primary complaint of people with hearing loss is understanding in noise, new hearing-aid technology works toward improving speech understanding while reducing listening effort in all environments. This significantly improves the individuals quality of life.

The negative effects of untreated hearing loss on quality of life are well-documented. Recent research has also confirmed a connection between many chronic health conditions including diabetes, cardiovascular disease, kidney disease, balance disorders, depression, and early-onset dementia and hearing loss. This research shows that hearing loss is not just an inevitable consequence of aging, but a health concern that should be treated as early as possible. My hope for the future is that all healthcare providers will recognize the value of optimal hearing in their patients overall health and well-being and, just as they monitor and treat other chronic health conditions, they will recommend early diagnosis and treatment of hearing loss.

See the original post:
The Region's Health Leaders on What's New and What the Next Decade Will Bring - Business West

Endothelial Dysfunction Industry 2019-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -…

The Asia-Pacific Endothelial Dysfunction market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Endothelium dysfunction can be defined as partial or complete loss of balance between vasodilating and vasoconstricting substances produced by the endothelium.

Ask for Sample Copy of This Report @https://www.orianresearch.com/request-sample/875202.

The Global Endothelial Dysfunction Industry based on geographic classification is studied for industry analysis, size, share, growth, trends, segment, top company analysis, outlook, manufacturing cost structure, capacity, supplier and forecast to 2025. Along with the reports on the global aspect, these reports cater regional aspects as well as global for the organizations

Top Key Vendors:

Abbott LaboratoriesChugai Pharmaceutical Co. Ltd.Johnson & JohnsonGlucox Biotech ABStealth Peptides Inc

Rise in number of obese populations, reduced physical activities and diabetes leading to increase in chances of acquiring cardiovascular diseases will propel the market growth in the forecast period. Stringent regulation regarding the drug will hamper the market growth in the forecast period. Advances in recombinant and gene therapy are also favoring the growth of endothelial dysfunction drugs uptake and can be an opportunity area for new entrants in the market.

Based on application, the market is segmented into, hospital, clinics among others.

Based on diagnosis, the market is segmented into, coronary circulation, angiography of coronary artery.

Based on region the market is segmented into China, India, Japan, South Korea, Taiwan, Southeast Asia, and Australia.

Global Endothelial Dysfunction Industry is spread across 121 pages, profiling 05 companies and supported with tables and figures.

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/875202.

Key Benefits of the Report:* Global, Regional, Country, Learning Module, and Type Market Size and Forecast from 2014-2025-Provide attractive market segments and associated growth opportunities* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies* Identification of key companies that can influence this market on a global and regional scale* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies* Detailed insights on emerging regions, product & Learning Module, and competitive landscape with qualitative and quantitative information and facts

Target Audience:* Endothelial Dysfunction providers* Traders, Importer and Exporter* Raw material suppliers and distributors* Research and consulting firms* Government and research organizations* Associations and industry bodies.

Order a copy of Global Endothelial DysfunctionMarket Report 2019 @https://www.orianresearch.com/checkout/875202

TABLE OF CONTENT

Introduction

Methodology & Scope

Global Endothelial Dysfunction Market Overview

Asia-Pacific Endothelial Dysfunction Market by Diagnosis type

Asia-Pacific Endothelial Dysfunction Market by Application

Asia-Pacific Endothelial Dysfunction Market by Region

Competitive Landscape

Company Profiles

End of TOC

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See the rest here:
Endothelial Dysfunction Industry 2019-2025 Market Analysis by Size, Share, Growth, Regional, Manufactures, Application and Forecast Research Report -...